Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Day One Biopharmaceuticals (DAWN) EBITDA (2023 - 2025)

Historic EBITDA for Day One Biopharmaceuticals (DAWN) over the last 3 years, with Q3 2025 value amounting to -$24.3 million.

  • Day One Biopharmaceuticals' EBITDA fell 18182.95% to -$24.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$165.6 million, marking a year-over-year increase of 2167.41%. This contributed to the annual value of -$217.3 million for FY2024, which is 543.81% down from last year.
  • According to the latest figures from Q3 2025, Day One Biopharmaceuticals' EBITDA is -$24.3 million, which was down 18182.95% from -$35.0 million recorded in Q2 2025.
  • Over the past 5 years, Day One Biopharmaceuticals' EBITDA peaked at $29.6 million during Q3 2024, and registered a low of -$114.8 million during Q2 2024.
  • Its 3-year average for EBITDA is -$47.8 million, with a median of -$50.3 million in 2023.
  • Per our database at Business Quant, Day One Biopharmaceuticals' EBITDA skyrocketed by 15761.5% in 2024 and then tumbled by 18182.95% in 2025.
  • Day One Biopharmaceuticals' EBITDA (Quarter) stood at -$59.5 million in 2023, then decreased by 9.77% to -$65.3 million in 2024, then surged by 62.88% to -$24.3 million in 2025.
  • Its EBITDA was -$24.3 million in Q3 2025, compared to -$35.0 million in Q2 2025 and -$41.1 million in Q1 2025.